State Letter #05-18
Centers for Disease Control and Prevention (CDC) Guidance to Health Care Providers Treating Sudanese and Somali Bantu refugees for Schistosomiasis and Strongyloidiasis
TO: STATE REFUGEE COORDINATORS
STATE REFUGEE HEALTH COORDINATORS
MUTUAL ASSISTANCE ASSOCIATIONS
FROM: Nguyen Van Hanh, Ph.D.
Office of Refugee Resettlement
SUBJECT: Centers for Disease Control and Prevention (CDC) Guidance to Health Care Providers Treating Sudanese and Somali Bantu refugees for Schistosomiasis and Strongyloidiasis
The attached CDC guidance should be shared with all Sudanese and Somali Bantu refugees and with health care providers treating these refugees. This technical guidance has been created for use by health care providers. Because many health care providers attending these refugees may not be familiar with schistosomiasis or strongyloidiasis, please make sure the appropriate providers receive the attached information.
If refugee service providers become involved with health care issues relevant to these refugee populations, they will also need to have this information at hand to pass along to their corresponding health care providers. Similarly, it may be helpful for Sudanese and Somali Bantu refugees themselves to have this guidance to pass along to their health care providers and to alert those providers of the advisability of presumptive treatment for these diseases.
The attached recommendations derive from similar recommendations made by the CDC for the presumptive treatment of the Sudanese Lost Boys and Girls for these same diseases.
ORR anticipates that the majority of treatment costs will be covered by state Medicaid programs, but if you experience difficulty in obtaining coverage for the recommended presumptive treatment, please call CDC or OGHA for guidance. Additionally, Schering-Plough has made the treatment for schistosomiasis (Biltricide/praziqunatel) available through its patient-assistance program. Sudanese and Somali Bantu refugees with low income or limited health care coverage may be able to receive schistosomiasis medication through this program. For more information on how to access Schering-Plough's patient assistance program, please link to:
Questions regarding the CDC recommendations should be addressed to Dr. Drew Posey at the Division of Global Migration and Quarantine (404 498 1601; email@example.com).
If you have any other questions concerning this State letter, please contact Marta Brenden (ORR), 202-205-3589, or Arjun Prasad (OGHA), 301-443-7243